We can’t show the full text here under this license. Use the link below to read it at the source.
Tirzepatide in Hispanic/Latino Patients With Type 2 Diabetes: A Subgroup Analysis of the SURPASS Program
Tirzepatide treatment in Hispanic/Latino people with Type 2 diabetes: Results from a subgroup analysis
AI simplified
Abstract
decreased significantly from baseline by 1.9% to 2.7% in Hispanic/Latino patients and 1.7% to 2.5% in non-Hispanic/Latino patients treated with tirzepatide.
- Body weight decreased significantly in Hispanic/Latino patients by 5.3 kg to 12.4 kg and in non-Hispanic/Latino patients by 6.5 kg to 17.1 kg.
- Treatment-emergent adverse events occurred at similar rates in both Hispanic/Latino and non-Hispanic/Latino subgroups, primarily involving gastrointestinal disorders.
- The incidence of hypoglycemia was low across both ethnic groups.
- Efficacy and safety trends were consistent between Hispanic/Latino and non-Hispanic/Latino patients within the overall trial populations.
AI simplified
Key numbers
1.9% to 2.7%
Reduction
Reduction from baseline in Hispanic/Latino patients.
5.3 kg to 12.4 kg
Body Weight Reduction
Change from baseline in Hispanic/Latino patients.
6.5 kg to 17.1 kg
Body Weight Reduction
Change from baseline in non-Hispanic/Latino patients.